A cross-sectional time series analysis

Biologic drugs are compounds derived from living organisms that are important treatment options across a number of medical indications. A biosimilar is a drug that is highly similar and has no clinically meaningful differences to an innovator biologic that has already been authorized for sale, but with a significantly lower price.

The ODPRN used real-world data in Ontario to estimate the number of patients potentially impacted by different biosimilar policy options and the cost implications of these policies. Three people with lived experience using biologics participated on the study team.

Access the full article and associated resources: